United States: Under FDA approval, the new pharmaceutical drug received authorization to treat a severe heart disease that affects diverse population groups.
More about the news
Alnylam Pharmaceuticals creates Amvuttra (vutrisiran) as a medication specifically designed for transthyretin amyloid cardiomyopathy (ATTR-CM).
Unhealthy proteins collected within the heart muscle create difficulty in blood pumping, according to the American Heart Association (AHA) assessment of ATTR-CM.
Independent testing demonstrated that Amvuttra reduced both heart problems and death chances by 28% throughout a three-year period versus receiving a placebo, US News reported.
The drug treatment requires monthly intravenous injections. The treatment presents an extremely expensive proposition to patients seeking relief.
Alnylam's Amvuttra receives FDA approval for a rare form of heart disease, entering a competitive market alongside Pfizer and BridgeBio Pharma for a profitable opportunity.https://t.co/vCvmkMnlQL
— Bio Data Studio (@BioDataStudio) March 24, 2025
The cost of each injection reaches USD 119,000, while the yearly expenses amount to USD 476,000.
The drug price from BridgeBio exceeds this medication by a large margin and stands above Pfizer’s available pill treatments for the same condition.
The drug remains expensive, which creates accessibility issues for patients using Medicare Advantage, especially for the annual drug expenditure of USD 476,000.
Certain private insurance providers tend to select Pfizer and BridgeBio pill alternatives due to their lower costs.
This drug operates in an exclusive method compared to other drugs in the market. The drug stops protein manufacturing through an RNA-based approach, whereas these treatments protect proteins from causing damage.
During testing, the BridgeBio medication demonstrated a reduction of 42% in both heart hospital admissions and mortality rates throughout a thirty-month timeframe.
The results from Amvuttra’s research indicated a 28% decline within three years. Different testing procedures prevent a direct comparison between the study findings, as US News reported.
Amvuttra has received market approval to treat the nerve-dominant type of ATTR. The new approval from regulators enables Alnylam to expand access to their drug to additional patients.